KCA
Search
- Page Path
- HOME > Search
Original Article
- Gastrointestinal cancer
- Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
- Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukherjee, Supeecha Kumkate, Tavan Janvilisri, Abed M Zaitoun, Thiti Kuakpaetoon, Rutaiwan Tohtong, Anna M Grabowska, David O. Bates, Kanokpan Wongprasert
- Cancer Res Treat. 2021;53(2):457-470. Published online October 7, 2020
- DOI: https://doi.org/10.4143/crt.2020.585
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed no survival benefits of erlotinib in patients with advanced CCA, the outcome of the standard-of-care chemotherapy treatment for CCA, gemcitabine/cisplatin, is discouraging so we determined the effect of other ErbB receptor inhibitors alone or in conjunction with chemotherapy in CCA cells. Materials and Methods ErbB receptor expression was determined in CCA patient tissues by immunohistochemistry and digital-droplet polymerase chain reaction, and in primary cells and cell lines by immunoblot. Effects on cell viability and cell cycle distribution of combination therapy using ErbB inhibitors with chemotherapeutic drugs was carried out in CCA cell lines. 3D culture of primary CCA cells was then adopted to evaluate the drug effect in a setting that more closely resembles in vivo cell environments.
Results
CCA tumors showed higher expression of all ErbB receptors compared with resection margins. Primary and CCA cell lines had variable expression of erbB receptors. CCA cell lines showed decreased cell viability when treated with chemotherapeutic drugs (gemcitabine and 5-fluorouracil) but also with ErbB inhibitors, particularly afatinib, and with a combination. Sequential treatment of gemcitabine with afatinib was particularly effective. Co-culture of CCA primary cells with cancer-associated fibroblasts decreased sensitivity to chemotherapies, but sensitized to afatinib. Conclusion Afatinib is a potential epidermal growth factor receptor targeted drug for CCA treatment and sequential treatment schedule of gemcitabine and afatinib could be explored in CCA patients. -
Citations
Citations to this article as recorded by
- Rational synthesis and evaluation of 2,4-diamino-thieno[2,3-d]pyrimidines as antitumor agents
Yumeng Gao, Ainv Zhang, Li Li, Fengxu Wu, Yanggen Hu
Journal of Saudi Chemical Society.2024; 28(1): 101794. CrossRef - Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma
Apiwit Sae-fung, Apiwat Mutirangura, Siriporn Jitkaew
Frontiers in Immunology.2023;[Epub] CrossRef - Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma
Kyaw Zwar Myint, Mireia Sueca-Comes, Pamela Collier, Brinda Balasubramanian, Simran Venkatraman, John Gordan, Abed M. Zaitoun, Abhik Mukherjee, Arvind Arora, Noppadol Larbcharoensub, Chinnawut Suriyonplengsaeng, Kanokpan Wongprasert, Tavan Janvilisri, Dha
Frontiers in Oncology.2023;[Epub] CrossRef - CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in Opisthorchis viverrini-Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS
Jinchutha Duangdara, Boonyakorn Boonsri, Apinya Sayinta, Kittiya Supradit, Pakpoom Thintharua, Supeecha Kumkate, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Somkit Mingphruedhi, Narongsak Rungsakulkij, Paramin Muangkaew, Pongsatorn Tangtawee, Wa
Pharmaceuticals.2023; 17(1): 9. CrossRef - Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis
Ubonrat Thamrongwaranggoon, Marutpong Detarya, Wunchana Seubwai, Charupong Saengboonmee, Shinjiro Hino, Tomoaki Koga, Mitsuyoshi Nakao, Sopit Wongkham
Life Sciences.2022; 302: 120648. CrossRef - Advances of cancer-associated fibroblasts in liver cancer
Hao Peng, Erwei Zhu, Yewei Zhang
Biomarker Research.2022;[Epub] CrossRef - RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach
Brinda Balasubramanian, Simran Venkatraman, Tavan Janvilisri, Tuangporn Suthiphongchai, Siriporn Jitkaew, Jittiyawadee Sripa, Rutaiwan Tohtong
Pharmaceuticals.2021; 14(9): 898. CrossRef
- Rational synthesis and evaluation of 2,4-diamino-thieno[2,3-d]pyrimidines as antitumor agents
- 10,280 View
- 397 Download
- 7 Crossref
First
Prev
